(Q40964830)

25 September 2017

1 reference

title

Lipoproteins and the progression/regression of atherosclerosis (English)

1 reference

25 September 2017

Barth JD

1

1 reference

25 September 2017

language of work or name

1 reference

1 October 1995

1 reference

Bailliere's clinical endocrinology and metabolism

25 September 2017

published in

1 reference

25 September 2017

volume

9

1 reference

25 September 2017

issue

4

1 reference

25 September 2017

page(s)

849-866

1 reference

Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial.

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Progression and regression of atherosclerosis, what roles for LDL-cholesterol and HDL-cholesterol: a perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Treatment of Kawasaki syndrome with intravenous gamma globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Relation of serum total cholesterol and triglyceride levels to the amount and extent of coronary arterial narrowing by atherosclerotic plaque in coronary heart disease. Quantitative analysis of 2,037 five mm segments of 160 major epicardial coronary

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Pravastatin, lipids, and major coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Various intensities of leisure time physical activity in patients with coronary artery disease: effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Lipoprotein Lipase: Its physiological and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Accumulation of intermediate density lipoprotein in plasma after intravenous administration of hepatic triglyceride lipase antibody in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

The value of lowering cholesterol after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Ultrasonographically assessed carotid morphology and the risk of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Natural history of coronary atherosclerosis using quantitative angiography in men, and implications for clinical trials of coronary regression. The Harvard Atherosclerosis Reversibility Project Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Mortality from circulatory diseases in Norway 1940-1945

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Canadian Coronary Atherosclerosis Intervention Trial Investigators Montreal, Ottawa, and Toronto, Ca

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980193-6

7 January 2021

10.1016/S0950-351X(95)80193-6

Identifiers

DOI

1 reference

25 September 2017

1 reference